Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BIA for Perioperative Fluid Evaluation in Colorectal Surgery
NCT07404527Recruiting
- Sponsor
- Institute of Oncology Ljubljana
- Start
- Oct 2023
- Primary completion
- Dec 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of cetuximab in head and neck cancer (HNC), sponsored by Institute of Oncology Ljubljana. Primary endpoint: Overall Survival at 5 years. Started Oct 2023; status: recruiting.
02
Drugs
cetuximab
03
Conditions
head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT07404527.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07404527.